What Changed
- Upcoming establishment of the Hong Kong Centre for Medical Products Regulation within the year for independent device assessment.
- Approval of 100 Hong Kong medical devices for 71 Greater Bay Area institutions under Medicine and Equipment Connect and NMPA acceptance of HK clinical data.
- Establishment of a joint cross-boundary clinical trial platform at Hetao for sharing data and biological samples between Hong Kong and Shenzhen.
# Hong Kong’s Regulatory and Capital Ecosystem for Surgical Robotics and Medical Technology Innovation
**Background**
On November 9, 2026, the Financial Secretary of the Hong Kong Special Administrative Region, Mr Paul Chan, delivered an opening address at the inaugural Surgical Futures Forum. Organised by Cornerstone Robotics, the forum brought together industry, academic, and medical leaders under the theme "Redefining Access to Surgical Care Through Robotics and Innovation."
The speech contextualised the current global state of surgical robotics. Twenty-five years ago, in 2001, a landmark transatlantic operation saw a surgeon in New York remove a patient’s gallbladder in Strasbourg, France. Despite a quarter-century of technological progress and millions of robot-assisted operations performed annually, global adoption of surgical robotics remains below 5 per cent. High system costs, large equipment footprints, and extensive training requirements for mainstream systems currently limit widespread installation outside of highly resourced healthcare facilities. Financial Secretary Chan emphasized that while the first 25 years focused on proving precision, the next phase must center on broadening patient access globally.
**Capital Mechanisms and Commercial Milestones**
Hong Kong's role in advancing medical technology extends beyond capital allocation to international commercialization. In September, medical technology enterprise Medtronic announced a strategic investment of approximately US$700 million in Cornerstone Robotics. Under this arrangement, Medtronic secured distribution rights for Cornerstone's Sentire Surgical System in selected international markets to complement its own platform. Following the announcement, the Sentire system was installed at the Institut de Recherche contre les Cancers de l'Appareil Digestif (IRCAD) in Strasbourg, France, a leading surgical training centre.
To support long-term technological development, Hong Kong relies on targeted financial mechanisms:
1. **Patient Capital:** The Hong Kong Investment Corporation (HKIC) serves as the territory's flagship for patient capital, funding medical technology and biotechnology growth through successive stages of research and commercialization.
2. **Biotech Listing Regime:** Following structural reforms introduced in 2018, pre-revenue and research-and-development stage biotechnology companies are permitted to raise capital on the Hong Kong Stock Exchange. Since the reform's inception, more than 90 biotech entities—including surgical robotics developers—have listed, positioning Hong Kong as the world’s second-largest biotechnology fundraising centre.
**Regulatory Framework and Cross-Border Integration**
Hong Kong is advancing its regulatory infrastructure to streamline drug and medical device evaluations while facilitating cross-border healthcare integration with Mainland China:
* **Hong Kong Centre for Medical Products Regulation:** Scheduled to be established within the year, this body aims to advance Hong Kong toward independent assessment and approval of pharmaceutical products and medical devices.
* **Medicine and Equipment Connect:** Under this scheme, 100 medical devices used in Hong Kong have received approval for operational use across 71 designated healthcare institutions in the Greater Bay Area (GBA).
* **NMPA Clinical Data Recognition:** Clinical data generated in Hong Kong are accepted by Mainland China’s National Medical Products Administration (NMPA). This provides a regulatory bridge for medical products validated in Hong Kong to obtain recognition across the Greater Bay Area and national Mainland markets, alongside international pathways.
* **Hetao Cross-Boundary Clinical Platform:** At Hetao, the Greater Bay Area International Clinical Trial Institute and the Shenzhen Park have jointly created a cross-boundary platform for clinical trials. This platform permits the shared use of clinical data and biological samples across the boundary to accelerate medical device and pharmaceutical research.
* **Academic Infrastructure:** Hong Kong currently houses two medical schools ranked among the world's top 30, with the Hong Kong University of Science and Technology establishing a third medical school focused on research and innovation.
**National AI+ Initiative and Public Healthcare Integration**
In parallel with hardware development, artificial intelligence (AI) integration forms a core component of public health strategy. Under China's national "AI+ Initiative", public well-being represents one of six primary priorities, calling for AI to reinforce primary healthcare.
In Hong Kong, the "AI+" framework is featured in the territory's Five-Year Plan, designating healthcare among the initial target sectors for coordinated action. Public hospitals in Hong Kong currently deploy AI technologies to analyse pathology slides, process medical images, and identify high-risk patients early to enable proactive clinical intervention.
---
### Frequently Asked Questions
**Q1: What is the current global penetration rate of surgical robotics mentioned in the source?**
According to industry figures cited in the speech, global adoption of surgical robotics remains in single digits, specifically below 5 per cent, due to high system costs, large footprints, and training constraints.
**Q2: What commercial agreement was announced between Medtronic and Cornerstone Robotics?**
In September, Medtronic announced a strategic investment of about US$700 million in Cornerstone Robotics and secured distribution rights for the Sentire Surgical System in selected international markets.
**Q3: How many biotech companies have listed in Hong Kong under the 2018 listing reform?**
More than 90 research-and-development stage biotech companies have listed in Hong Kong since the 2018 listing regime reform was introduced, making Hong Kong the world's second-largest biotech fundraising centre.
**Q4: How does the "Medicine and Equipment Connect" scheme operate in the Greater Bay Area?**
Under the scheme, 100 medical devices used in Hong Kong have been approved for use across 71 designated institutions throughout the Greater Bay Area.
**Q5: What facility has been established at Hetao for clinical research?**
The Greater Bay Area International Clinical Trial Institute and the Shenzhen Park have jointly established a cross-boundary platform at Hetao, enabling the cross-border use of clinical data and biological samples.
Who May Be Affected
Medical device manufacturers, surgical robotics companies, biotechnology investors, healthcare institutions, and clinical researchers in Hong Kong SAR, Mainland China, and international jurisdictions.
Cross-Border Context
Cross-border regulatory alignment between Hong Kong SAR and Mainland China, including NMPA clinical data acceptance, Greater Bay Area medical device approvals under Medicine and Equipment Connect, and joint clinical trial data/sample sharing at Hetao.
What to check next
- Official launch announcements and legislative/regulatory texts for the Hong Kong Centre for Medical Products Regulation.
- Updated lists of approved medical devices and participating institutions under the Medicine and Equipment Connect scheme.
- Operational guidelines governing cross-border transfers of biological samples and clinical data at the Hetao cross-boundary platform.
This article provides general information and does not constitute legal advice. Consult the official text and obtain advice appropriate to your circumstances where needed.